BAF15. Likewise, with À7.8 kcal/mol BAF22 has a very weak 5 0 -end of the antisense strand compared to À12.2 kcal/mol for BAF24. In addition, the 5 0 -end of the antisense strand is much weaker than the 5 0 -end of the sense strand (À7.8 vs À12.1 kcal/ mol). According to the current models for siRNA activity, the thermodynamic properties of BAF22 can explain its superior activity compared to BAF24.
Acadesine induces apoptosis in B cells from mantle cell lymphoma and splenic marginal zone lymphoma Leukemia (2005) Mature B-cell neoplasms include B-cell chronic lymphocytic leukemia (B-CLL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and splenic marginal zone B-cell lymphoma (SMZL), among others. 1 These neoplasms have an increasing incidence in Western countries, where they account for about 75% of all lymphoid neoplasms. Therapeutic options for mature B-cell neoplasms include alkylating agents, purine nucleoside analogues, combination chemotherapy, interferon, and monoclonal antibodies. Although most patients respond to chemotherapy, these neoplasms are characterized by a continuous pattern of relapse and there is no standard treatment. [2] [3] [4] Moreover, current chemotherapeutic agents are not selective for tumor cells and consequently they have several negative effects on the quality of life of those treated. For instance, purine analogues induce apoptosis of T cells, which leads to immunosuppression. Thus, new therapeutic drugs with a differential effect on B and T lymphocytes are of great interest.
Blood samples from patients with peripheral blood manifestation of the disease contain both tumor and normal lymphocytes. Thus, analysis of drug-induced apoptosis in the B-cell and T-cell population by flow cytometry is a useful method to study the cell-type selectivity of anticancer drugs or combinations. 5 We have previously reported that acadesine (5-aminoimidazole-4-carboxamide riboside, AICAR) induces apoptosis in B cells from B-CLL patients. 5 This apoptotic effect is caspase-dependent and p53-independent. Normal B lymphocytes are as sensitive as B-CLL cells to acadesine-induced apoptosis, while T lymphocytes are resistant. Here, we examine whether acadesine induces apoptosis in cells from other mature B-cell neoplasms.
After informed consent, peripheral blood samples of SMZL, MCL, and FL patients from the Hematology Unit at the Hospital Universitari de Bellvitge (Barcelona, Spain) were collected. Diagnosis was based on clinical, morphologic, immunophenotypic and molecular criteria following the WHO classification. 1 A total of 34 patients were included (21 SMZL, eight MCL and five FL). Eight of the 21 SMZL samples and six of the eight MCL samples were positive for CD5, determined by flow cytometry. All MCL samples were positive for cyclin D1 expression, as measured by immunohistochemistry. All FL samples were positive for CD10 and Bcl-2, negative for CD5, and all of them were low grade FL (with no transformation). All samples were positive for CD19, CD20 and presented clonality of surface immunoglobulins.
Briefly, mononuclear cells were isolated from peripheral blood by centrifugation on a Ficoll/Hypaque gradient and cultured in RPMI 1640 medium, 10% heat-inactivated fetal bovine serum, 2 mmol/l glutamine, 100 U penicillin and 100 ng/ ml streptomycin, as previously described. 5 The percentage of B and T cells in the isolated mononuclear cells was determined by flow cytometry by coincubation with APC-conjugated anti-CD3 and PE-conjugated anti-CD19 antibodies (Becton Dickinson, Mountain View, CA, USA) immediately after isolation (Table 1) . Cells from each sample were incubated for 24 h with increasing doses of acadesine (Toronto Research Chemicals Inc., North York, Canada) ranging from 0.2 to 2 mM, 3 mM fludarabine or 10 mM chlorambucil, and apoptosis in B and T cells was quantified by surface annexin V staining as previously described. 5 A live-gate for the CD19 þ /CD3À cells (B-cell population) and for the CD19À/CD3 þ cells (T-cell population) Effect of acadesine on B cells from SMZL, MCL and FL. Peripheral lymphocytes from patients were incubated for 24 h with increasing doses of acadesine ranging from 0.2 to 2 mM. The EC 50 (half-maximal effective concentration) for each sample is shown in the figure. We consider that a sample is resistant when there is no apoptotic effect at 2 mM anadesine.
was drawn and the percentages of nonapoptotic and apoptotic cells were determined for each population (Figure 1) . Viability was expressed as the percentage of nonapoptotic cells. Samples were acquired and data were analyzed using Cell Quest software (Becton Dickinson).
We observed a dose-dependent decrease in B-cell viability in the 21 SMZL samples treated with acadesine, and the mean EC 50 (half-maximal effective concentration) for SMZL B cells was 1.270.7 mM (Figure 2) . Moreover, acadesine induced apoptosis in B cells from seven of the eight MCL patients and one sample from FL. B cells from one MCL sample (patient 29) and four of the five FL samples were resistant to acadesine at doses up to 2 mM. At 2 mM, acadesine did not induce apoptosis in T cells from any of the 34 samples from mature B-cell neoplasms (results from one sample are shown in Figure 1 ), which is consistent with our previous report on T cells from B-CLL patients or healthy donors. 5 The alkylating agent chlorambucil, and the nucleoside analogue fludarabine have been used in the treatment of SMZL patients. 6 Thus, we analyzed the apoptotic effect of 3 mM fludarabine and 10 mM chlorambucil, which correspond to the therapeutically achievable plasmatic levels of these drugs. Cells from the four patients studied responded to acadesine in a dose-dependent manner. However, only one of the four samples (patient 17) responded to fludarabine and chlorambucil ex vivo (Figure 3) .
The mechanism of acadesine-induced apoptosis is unknown. Incorporation of acadesine into the cell and its subsequent phosphorylation to AICA ribotide (ZMP) are necessary to induce apoptosis in B-CLL cells. 5 The only molecular target of ZMP described to date is adenosine monophosphate-activated protein kinase (AMPK), and acadesine induces the activation of AMPK in B-CLL cells. In contrast, in Jurkat cells, inhibition of ZMP synthesis does not inhibit acadesine-induced apoptosis. 7 The involvement of AMPK in acadesine-induced apoptosis in B cells requires further investigation. Preliminary data suggest that acadesine does not induce p53 accumulation in SMZL or MCL cells (data not shown), as described for B-CLL cells. 5 Most FL samples were resistant to acadesine-induced apoptosis. All FL analyzed were low-grade FL, thus we cannot rule out that other types could be more sensitive to acadesine. Acadesine enters FL cells as it induces phosphorylation of AMPK (results not shown). Bcl-2 is overexpressed in both FL and B-CLL; however, B-CLL cells are sensitive to acadesine-induced apoptosis. It would be very interesting to analyze this resistance as it could provide clues to understand the mechanism of acadesine-induced apoptosis.
Previous clinical studies in patients show that acadesine is well tolerated by healthy individuals when administered intravenously, and plasma concentrations in the range of those producing apoptosis in B cells (0.3 mM) 8 are achieved. In conclusion, on the basis of our results, we propose that acadesine may provide an effective treatment for mature B-cell neoplasms such as SMZL and MCL. Effect of acadesine, fludarabine and chlorambucil on SMZL cells. Mononuclear cells from 4 SMZL samples were cultured with 0.5 mM (0.5), 1 mM (1) or 2 mM (2) acadesine, 3 mM fludarabine (F) or 10 mM chlorambucil (Clb) for 24 h. Viability was measured by analysis of phosphatidylserine exposure in the CD19 þ population, as described in the text. Cell viability is expressed as the percentage of non-apoptotic cells with respect to control cells at 24 h of culture.
